Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam-Reference-Cited by-同舟云学术

Using Therapeutic Drug Monitoring to Treat KPC-Producing Klebsiella pneumoniae Central Nervous System Infection With Ceftazidime/Avibactam

Published:2020-08-18 Issue:9 Volume:7 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Yasmin Mohamad¹^ORCID,Hanrahan Jennifer²,Marshall Steven¹,Lodise Thomas P³,Chen Liang⁴⁵,Perez Federico¹⁶⁷,Kreiswirth Barry⁴⁵,Bonomo Robert A¹⁶⁷⁸⁹

Affiliation:

1. Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA

2. Division of Infectious Diseases, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA

3. Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA

4. Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA

5. Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, NJ, USA

6. Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA

7. Geriatric Research, Education and Clinical Center, Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio, USA

8. Departments of Molecular Biology & Microbiology, Pharmacology, Biochemistry, and Proteomics & Bioinformatics, Case Western Reserve University, Cleveland, Ohio, USA

9. CWRU-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA

Abstract

Abstract This report describes the treatment of Klebsiella pneumoniae carbapenemase (KPC)–3–producing multidrug-resistant K. pneumoniae with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC–Klebsiella pneumoniae central nervous system infections.

Funder

National Institute of Allergy and Infectious Diseases

National Institutes of Health

Cleveland Department of Veterans Affairs

Biomedical Laboratory Research and Development, VA Office of Research and Development

Geriatric Research Education and Clinical Center

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofaa349/33658929/ofaa349.pdf

Reference17 articles.

1. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae;Endimiani;Antimicrob Agents Chemother,2011

2. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase–producing Enterobacteriaceae;Won;Clin Infect Dis,2011

3. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation β-lactam/β-lactamase inhibitor combinations;van Duin;Clin Infect Dis,2016

4. Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae;van Duin;Clin Infect Dis,2018

5. Pharmacokinetics of the new β-lactamase inhibitor NXL104 in an experimental rabbit meningitis model: restoration of the bacteriological efficacy of ceftazidime (CAZ) against a class C producing K pneumoniae.;Cottagnoud,2007

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous post-neurosurgical ventriculitis and bacteraemia by two different strains of KPC-producing K. pneumoniae successfully treated with meropenem/vaborbactam and high dose of fosfomycin;Journal of Global Antimicrobial Resistance;2024-06

2. A Difficult Case of Ventriculitis in a 40-Year-Old Woman with Acute Myeloid Leukemia;Antibiotics;2024-05-10

3. Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam;Clinical Infectious Diseases;2024-04-17

4. Meropenem–Vaborbactam for the Treatment of Post-Neurosurgical Meningitis Caused by KPC Producer Klebsiella Pneumoniae: A Case Report and Review of the Literature;Antibiotics;2024-04-05

5. The pharmacokinetics/pharmacodynamics of ceftazidime/avibactam for central nervous system infections caused by carbapenem-resistant Gram-negatives: a prospective study;Journal of Antimicrobial Chemotherapy;2024-02-15